DB-1303-O-1001: A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Full Title
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors

Study Treatment
HER2 targeting antibody drug conjugate DB-1303/BNT323

Eligibility/Info
Cohort 2p: HER2-low to -positive metastatic endometrial cancer previously treated with platinum chemotherapy and immunotherapy.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage

Need More Information?

Our team is here to help answer your questions and guide you through your options.